Posted by Michael Wonder on 28 Mar 2018
Shield receives EU Commission approval for the broadening of the indication for Feraccru (ferric maltol) to the treatment of iron deficiency in adults
27 March 2018 - Shield Therapeutics today announces that the European Commission has adopted the Decision to extend the approved indication for Feraccru to include treatment of all adults with iron deficiency with or without anaemia.
This decision, which follows the recent positive opinion of the CHMP of the EMA to adopt this extension of Feraccru’s marketing authorisation approval, will provide Feraccru with a much broader commercial opportunity, as previously it was only approved and marketed in Europe for the treatment of iron deficiency anemia in adult patients with inflammatory bowel disease.
